Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
Introduction: Preclinical studies have suggested that metformin has antitumor effects, likely due to blockage of mTOR pathway through AMPK and decreased insulin levels. A retrospective study showed that metformin combined with everolimus to treat related hyperglycemia offered longer progression-free survival (PFS) in patients (pts) with pancreatic neuroendocrine tumors (NET).
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Glasberg J
Authors: Glasberg J, Talans A, Lopez R, Recchimuzzi D, Riechelmann R,
Keywords: neuroendocrine tumors, metformin, clinical trial,
#2001 The Anticancer Mechanism of Metformin in Pancreatic Neuroendocrine Tumor Cells
Introduction: Metformin, a widely used antidiabetic drug, has been reported to display potent anticancer properties in various types of cancers. In P-NETs, aryl hydrocarbon receptor-interacting protein (AIP) acts as a tumor suppressor and is up-regulated by the somatostatin analog octreotide.
Conference: 15th Annual ENETSConcerence (2018)
Presenting Author: Lania A
Authors: Vitali E, Piccini S, Boemi I, Brambilla T, Zerbi A,
Introduction: Anti proliferative effect of LAN ATG 120 mg has been investigated in 204 GI-NET pts in Clarinet study with a 53% reduction in risk of death/progression vs placebo. An increasing number of trials have associated MET with better outcome in cancer pts due to a reduction of insulin/IGF1 levels and modulation of AMPK and TSC1-2/mTOR. The retrospective PRIME-net study conducted on 445 Italian pts, suggest that addition of MET to everolimus and/or SSA provides clinical benefit in diabetic pancreatic NETs.
Conference: 14th Annual ENETSConcerence (2017)
Presenting Author: pusceddu s
Authors: Prinzi N, Femia D, Concas L, Lo Russo G, Vernieri C,
Keywords: lanreotide, metformin,
Introduction: MET has shown antitumorigenic effects on DM cancer pts, which are mediated by decrease of insulin/IGF-1 levels and activation of the AMPK pathway leading to mTOR inactivation.
Conference: 12th Annual ENETSConcerence (2015)
Presenting Author: Custodio A
Authors: Custodio A, Jiménez-Fonseca P, Alonso-Orduña V, López López C, Alonso T,
Keywords: NET, diabetes, metformin, everolimus,
#904 Role of Metformin on Recurrence-Free Survival (RFS) in Neuroendocrine Tumors (NET)
Introduction: Recent data suggest metformin (Met) has antineoplastic properties in different type of cancer. Effects of Met have never been investigated in NET.
Conference: 11th Annual ENETSConcerence (2014)
Presenting Author: Marciello F
Authors: Marciello F, Del Prete M, Marotta V, Ramundo V, Buonomano P,